1266 References 1. Anderson S, Rennke HG, Brenner BM (1986) Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77:1993–2000 2. Navar LG, Harrison-Bernard LM, Imig JD, Wang CT, Cervenka L, Mitchell KD (1999) Intrarenal angiotensin II generation and renal effects of AT1 receptor blockade. J Am Soc Nephrol 10 (Suppl 12): S266–272 3. Nakamura N, Soubrier F, Menard J, Panthier JJ, Rougeon F, Corvol P (1985) Nonproportional changes in plasma renin concentration, renal renin content, and rat renin messenger RNA. Hypertension 7:855–859 4. Wagner J, Volk S, Haufe CC, Ciechanowicz A, Paul M, Ritz E (1995) Renin gene expression in human kidney biopsies from patients with glomerulonephritis or graft rejection. J Am Soc Nephrol 5:1469–1475 5. Kagami S, Border WA, Miller DE, Noble (1994) Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest 93:2431–2437 6. Kagami S, Kuhara T, Okada K, Kuroda Y, Border WA, Noble (1997) Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells. Kidney Int 51:664–671 7. Ruiz-Ortega M, Egido J (1997) Angiotensin II modulates cell growth-related events and synthesis of matrix proteins in renal interstitial fibroblasts. Kidney Int 52:1497–1510 8. Mahmood J, Khan F, Okada S, Kumagai N, Morioka T, Oite T (2006) Local delivery of angiotensin receptor blocker into the kidney ameliorates progression of experimental glomerulonephritis. Kidney Int 70:1591–1598 9. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G (1998) Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril efficacy in nephropathy. Lancet 352:1252–1256 10. Horita Y, Tadokoro M, Taura K, Suyama N, Taguchi T, Miyazaki M, Kohno S (2004) Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immuno- globulin a nephropathy. Hypertens Res 27:963–970 11. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R (1998) Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 128: 982–988 12. Coppo R, D, Amico G (2005) Factors predicting progression of IgA nephropathies. J Nephrol 18:503–512 13. Schena FP (1990) A retrospective analysis of the natural history of primary IgA nephropathy worldwide. Am J Med 89:209–215 14. Yoshikawa N, Iijima K, Maehara K, Yoshiara S, Yoshiya K, Matsuo T, Okada S (1987) Mesangial changes in IgA nephropathy in children. Kidney Int 32:585–589 15. Tanaka H, Suzuki K, Nakahata T, Tsugawa K, Konno Y, Tsuruga K, Ito E, Waga S (2004) Combined therapy of enalapril and losartan attenuates histologic progression in immunoglobulin A nephropa- thy. Pediatr Int 46:576–579 16. Yang Y, Ohta K, Shimizu M, Nakai A, Kasahara Y, Yachie A, Koizumi S (2005) Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy. Clin Nephrol 64:35–40 17. Del Prete D, Gambaro G, Lupo A, Anglani F, Brezzi B, Magistroni R, Graziotto R, Furci L, Modena F, Bernich P, Albertazzi A, D’ Angelo A, Maschio G (2003) Precocious activation Pediatr Nephrol (2008) 23:1257–1267 of genes of the renin-angiotensin system and the fibrogenic cascade in IgA glomerulonephritis. Kidney Int 64:149–159 18. Kobori H, Ozawa Y, Suzaki Y, Prieto-Carrasquro MC, Nishiyama A, Shoji T, Cohen EP, Navar LG (2006) Yong scholars award lecture: intratubular angiotensinogen in hypertension and kidney diseases. Am J Hypertens 19:541–550 19. Lee LK, Meyer TW, Pollock AS, Lovett DH (1995) Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney. J Clin Invest 96:953–964 20. Singh R, Singh AK, Leehey DJ (2005) A novel mechanism for angiotensin II formation in streptozotocin-diabetic rat glomeruli. Am J Physiol Renal Physiol 288:F1183–F1190 21. Kobori H, Ozawa Y, Suzaki Y, Nishiyama A (2005) Enhanced intrarenal angiotensinogen contributes to early renal injury in spontaneously hypertensive rats. J Am Soc Nephrol 16:2073–2080 22. Shin GT, Kim WH, Yim H, Kim MS, Kim H (2005) Effects of suppressing intrarenal angiotensinogen on renal transforming growth factor-β1 expression in acute ureteral obstruction. Kidney Int 67:897–908 23. Churg J, Bernstein J, Glassock R (1995) Classification of glomerular disease. In: Churg J, Bernstein J, Glassoch R (eds), Renal disease: classification and atlas of glomerular disease, 2nd end. Igaku-Shoin, New York, pp 1–23 24. Miyake-Ogawa C, Miyazaki M, Abe K, Harada T, Ozono Y, Sakai H, Koji T, Kohno S (2005) Tissue-specific expression of renin-angiotensin system components in IgA nephropathy. Am J Nephrol 25:1–12 25. Kuhara T, Kagami S, Kuroda Y (1997) Expression of b1-integrins on activated mesangial cells in human glomerulonephritis. J Am Soc Nephrol 8:1679–1687 26. Ballardie FW, Roberts IS (2002) Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 13:142–148 27. Kondo S, Shimizu M, Urushihara M, Tsuchiya K, Yoshizumi M, Tamaki T, Nishiyama A, Kawachi H, Shimizu F, Quinn MT, Lambeth DJ, Kagami S (2006) Addition of the antioxidant probucol to angiotensin II type I receptor antagonist arrests progressive mesangioproliferative glomerulonephritis in the rat. J Am Soc Nephrol 17:783–794 28. Abe K, Miyazaki M, Koji T, Furusu A, Nakamura-Kurashige T, Nishino T, Ozono Y, Harada T, Sakai H, Kohno S (2001) Enhanced expression of complement C5a receptor mRNA in human diseased kidney assessed by in situ hybridization. Kidney Int 60:137–146 29. Suzaki Y, Ozawa Y, Kobori H (2006) Quantification of human angiotensinogen by a novel sandwich ELISA. Peptides 27:3000–3002 30. Murakami S, Morioka T, Nakagawa Y, Suzuki Y, Arakawa M, Oite T (2001) Expression of adhesion molecules by cultured human glomerular endothelial cells in response to cytokines: comparison to human umbilical vein and dermal microvascular endothelial cells. Microvasc Res 62:383–391 31. Gimenez-Roqueplo AP, Celerier J, Lucarelli G, Corvol P, Jeunemaitre X (1998) Role of N-glycosylation in human angiotensinogen. J Biol Chem 273:21232–21238 32. Wake DJ, Rask E, Livingstone DE, Soderberg S, Olsson T, Walker BR (2003) Local and systemic impact of transcriptional up- regulation of 11b-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity. J Clin Endorinol Metab 88:3983–3988 33. Kobori H, Harrison-Bernard LM, Navar LG (2001) Expression of angiotensinogen mRNA and protein in angiotensin II-dependent hypertension. J Am Soc Nephrol 12:431–439 34. Liebau MC, Lang D, Bohm J, Endlich N, Bek MJ, Witherden I, Mathieson PW, Saleem MA, Pavenstadt H, Fischer KG (2006) Functional expression of the renin-angiotensin system in human podocytes. Am J Physiol Renal Phyiol 290:710–719 35. Lai KN, Leung JC, Lai KB, To WY, Yeung VT, Lai FM (1998) Gene expression of the renin-angiotensin system in human kidney. J Hypertens 16:91–102